99 active not recruiting, 82 completed, 40 recruiting, 36 terminated. 168 Phase 2, 115 Phase 1, 29 Phase 3, 5 Early Phase 1, 1 Not applicable.
Follow ONO-4538: new trials by email Literature Review of ONO-4538 trials Research Report on ONO-4538
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older Anakinra, Biospecimen Collection, Computed Tomography - Melanoma | Phase 1 | Not yet recruiting | University of Southern California | 40 | 2026-11-01 | 2026-09-24 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 18 | 2026-04-21 | 2026-06-05 |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 43 | 2025-12-12 | 2026-10-02 |
| ONO-4538 Study in Patients With Richter's Transformation ONO-4538 - Richter's Transformation | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 14 | 2025-11-19 | 2026-02-13 |
| Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Acral Melanoma, Advanced Cutaneous Melanoma | Phase 2 | Recruiting | Emory University | 99 | 2025-10-29 | 2025-11-12 |
| Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung Aerosol Sargramostim, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung | Phase 1 | Withdrawn | Mayo Clinic | 2025-10-28 | 2025-08-07 | |
| Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 55 | 2025-08-15 | 2026-07-31 |
| Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy Atezolizumab, Biospecimen Collection, Cemiplimab - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Emory University | 20 | 2025-04-09 | 2026-02-12 |
| Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma Biospecimen Collection, Computed Tomography, Dacarbazine - Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Recruiting | University of Washington | 125 | 2025-03-06 | 2026-09-09 |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-12-01 | 2025-02-24 | |
| Study to ONO-4538 in Patients With Rhabdoid Tumor ONO-4538 - Rhabdoid Tumor | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 23 | 2024-11-25 | 2026-08-04 |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 184 | 2024-11-08 | 2026-10-19 |
| Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer Avutometinib, Biopsy, Biospecimen Collection - Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma | Phase 2 | Recruiting | Emory University | 50 | 2024-07-31 | 2026-04-06 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Biospecimen Collection, Bone Scan, Carboplatin - Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 156 | 2024-07-15 | 2026-10-21 |
Showing 20 of 283. Sign in to see all of them.
Melanoma (33) · Carcinoma, Non-Small-Cell Lung (30) · Carcinoma, Renal Cell (28) · Lung Neoplasms (25) · Neoplasm Metastasis (16) · Carcinoma, Hepatocellular (14) · Squamous Cell Carcinoma of Head and Neck (13) · Colorectal Neoplasms (12) · Hodgkin Disease (12) · Clear-cell metastatic renal cell carcinoma (9) · Leukemia, Myeloid, Acute (9) · Multiple Myeloma (9) · Pancreatic Neoplasms (9) · Prostatic Neoplasms (9) · Lymphoma, Large B-Cell, Diffuse (8)
National Cancer Institute (NCI) (83) · M.D. Anderson Cancer Center (40) · Ono Pharmaceutical Co., Ltd. (21) · Emory University (15) · City of Hope Medical Center (14) · Mayo Clinic (11) · Northwestern University (11) · Jonsson Comprehensive Cancer Center (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (5) · University of Washington (5) · SWOG Cancer Research Network (4) · Academic and Community Cancer Research United (3) · David Bond, MD (3) · Roswell Park Cancer Institute (3)
United States (251) · Canada (27) · Japan (21) · Puerto Rico (12) · South Korea (9) · Australia (7) · Taiwan (7) · Guam (4) · China (3) · Singapore (3) · Hong Kong (1) · Ireland (1) · Israel (1) · New Zealand (1) · Uganda (1)
Project Leader (13) · Mitsunobu Tanimoto (5) · Alex F Herrera (4) · Sumanta K Pal (4) · Brigette B Ma (3) · A P Chen (2) · Amir A Jazaeri (2) · Andrea B Apolo (2) · Catherine S Diefenbach (2) · Cathy Eng (2) · David Bond, MD (2) · Evan J Lipson (2) · Haider S Mahdi (2) · Jennifer Johnson, MD, PhD (2) · Lakshmi Rajdev (2)
PMID 37505794, PMID 29158363, PMID 33394722, PMID 35031545, PMID 35622074, PMID 11118469, PMID 12091876, PMID 12218188, PMID 15269160, PMID 1576319, PMID 15869455, PMID 15950727, PMID 16382236, PMID 1638557, PMID 1643631, PMID 17369569, PMID 19047298, PMID 19171714, PMID 19304016, PMID 19626208, PMID 19638464, PMID 20570856, PMID 20879881, PMID 21074057, PMID 21149662, PMID 21298742, PMID 21798350, PMID 22186141, PMID 22658127, PMID 22658128, PMID 22700000, PMID 22844125, PMID 23649004, PMID 23661160, PMID 23724867, PMID 24333097, PMID 24848257, PMID 2514231, PMID 25604432, PMID 26320062, PMID 26410619, PMID 26586415, PMID 26785755, PMID 27410923, PMID 28223062, PMID 28993052, PMID 29370992, PMID 29490632, PMID 29584545, PMID 29784747
U10CA180820 (17), U10CA180821 (14), P30CA033572 (11), P30CA060553 (11), P30CA138292 (11), U10CA180888 (11), U10CA180868 (10), UM1CA186691 (7), UM1CA186709 (6), U10CA180886 (5), UM1CA186689 (5), UM1CA186712 (5), P30CA015083 (4), P30CA016672 (4), U24CA196172 (4)